Evidence map›Paper›PMID 35867237›Full record

ArticleJournal of nephrology2023

Kynurenines in polycystic kidney disease.

Jost Klawitter, Matthew J Jackson, Peter H Smith, Katharina Hopp, Michel Chonchol, Berenice Y Gitomer, Melissa A Cadnapaphornchai, Uwe Christians, Jelena Klawitter

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Amino acid metabolism in kidney health and disease.Nature reviews. Nephrology · 2024
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jost KlawitterDepartment of Anesthesiology, University of Colorado School of Medicine, University of Colorado Denver Anschutz Medical Campus, 12705 E Montview Blvd, Bioscience 2, Suite 200, Aurora, CO, 80045-7109, USA.
Matthew J JacksonDepartment of Anesthesiology, University of Colorado School of Medicine, University of Colorado Denver Anschutz Medical Campus, 12705 E Montview Blvd, Bioscience 2, Suite 200, Aurora, CO, 80045-7109, USA.
Peter H SmithDepartment of Anesthesiology, University of Colorado School of Medicine, University of Colorado Denver Anschutz Medical Campus, 12705 E Montview Blvd, Bioscience 2, Suite 200, Aurora, CO, 80045-7109, USA.
Katharina HoppDivision of Renal Diseases and Hypertension, University of Colorado School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Michel ChoncholDivision of Renal Diseases and Hypertension, University of Colorado School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Berenice Y GitomerDivision of Renal Diseases and Hypertension, University of Colorado School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Melissa A CadnapaphornchaiDivision of Renal Diseases and Hypertension, University of Colorado School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Uwe ChristiansDepartment of Anesthesiology, University of Colorado School of Medicine, University of Colorado Denver Anschutz Medical Campus, 12705 E Montview Blvd, Bioscience 2, Suite 200, Aurora, CO, 80045-7109, USA.
Jelena KlawitterDepartment of Anesthesiology, University of Colorado School of Medicine, University of Colorado Denver Anschutz Medical Campus, 12705 E Montview Blvd, Bioscience 2, Suite 200, Aurora, CO, 80045-7109, USA. Jelena.Klawitter@cuanschutz.edu.
University of Colorado Anschutz Medical Campus · USUniversity of Colorado Denver · US

Funding

Effect of Statin Therapy on Disease Progression in Children with ADPKDR01DK058793 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI SCHRIER, ROBERT W · 2001 to 2012
$4.8M
Defining the functional role of T-cells in Autosomal Dominant Polycystic Kidney Disease pathologyK01DK114164 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI HOPP, KATHARINA · 2018 to 2022
$783k
The role of inflammation in the progression of polycystic kidney diseaseR01DK114424 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI GITOMER, BERENICE YOLANDE, KLAWITTER, JELENA · 2018 to 2020
$668k
NIDDK NIH HHS K01 DK114164NIDDK NIH HHS R01 DK058793NIDDK NIH HHS R01 DK114424NIH HHS DK058793NIH HHS R01DK114424NIH HHS U01DK062404
6 · The paper itself

Abstract

backgroundAutosomal dominant polycystic kidney disease (ADPKD) is a common hereditary disorder, characterized by kidney cyst formation. A major pathological feature of ADPKD is the development of interstitial inflammation. Due to its role in inflammation and oxidative stress, tryptophan metabolism and related kynurenines may have relevance in ADPKD.

methodsData were collected from a well-characterized longitudinal cohort of pediatric and adult patients with ADPKD and compared to age-matched healthy subjects. To evaluate the role of kynurenines in ADPKD severity and progression, we investigated their association with height-corrected total kidney volume (HtTKV) and kidney function (estimated glomerular filtration rate (eGFR)). Key tryptophan metabolites were measured in plasma using a validated liquid chromatography-mass spectrometry assay.

resultsThere was a significant accumulation of kynurenine and kynurenic acid (KYNA) in children and adults with ADPKD as compared to healthy subjects. Downstream kynurenines continued to accumulate in adults with ADPKD concurrent with the increase of inflammatory markers IL-6 and MCP-1. Both markers remained unchanged in ADPKD as compared to healthy children, suggesting alternate pathways responsible for the observed rise in kynurenine and KYNA. KYNA and kynurenine/tryptophan positively associated with disease severity (HtTKV or eGFR) in patients with ADPKD. After Bonferroni adjustment, baseline kynurenines did not associate with disease progression (yearly %change in HtTKV or yearly change in eGFR) in this limited number of patients with ADPKD.

conclusionKynurenine metabolism seems dysregulated in ADPKD as compared to healthy subjects. Inhibition of kynurenine production by inhibition of main pathway enzymes could present a novel way to reduce the progression of ADPKD.

Indexed as

Polycystic Kidney, Autosomal DominantAdultChildDisease ProgressionGlomerular Filtration RateHumansInflammationKidneyKynurenineTryptophanKynurenineTryptophanADPKDKynureninesTryptophan

Identifiers

PMID35867237
PMCPMC9867782
OpenAlexW4286560755

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.